StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Net Sales in Rest of World by Quarter

Net Sales in Rest of World ($M)

QuarterlyAnnual

Novartis Net Sales in Rest of World: $764M in Q3 2026, up 10.2% from a year earlier.

Latest, Q3 2026
764
Period ended Sep 30, 2026
Change on a year earlier
+10.2%
693 in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Cosentyx | Immunology | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS) | 1 093 | 9 | 764 | 10 | 9 | 1 857 | 9 | 9”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in Rest of World ($M)Year on yearSource
Q3 2026Sep 30, 2026764+10.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026755+6.6%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026796+10.7%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025709+20.6%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025693-1.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025708+7.6%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025719+8.1%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024588+4.6%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024700+14.4%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024658+5.8%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024665+21.4%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023562+25.7%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023612+15.0%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023622+15.4%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023548+9.6%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022447-5.5%Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in Rest of World

Cite this data

StockData. (2026). Novartis Net Sales in Rest of World ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-cosentyx-row-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.